Strategier for reversering af non-vitamin K orale antikoagulantia
Sammanfattning
Non-vitamin K oral anticoagulants (NOACs) are alternatives to vitamin K antagonists and provide consistent anticoagulation with equal or
better clinical outcome and no need for routine monitoring. Bleeding is a feared complication of anticoagulants. Until recently, no specific
agent has been available for reversal of NOACs. Idarucizumab binds dabigatran for rapid reversal of its activity without procoagulant effects.
Andexanet alpha (expected release in 2016) and PER977 are antidotes under clinical development. This article summarizes current and
potential future options to antagonize NOACs.